Compare CAAS & CNTB Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | CAAS | CNTB |
|---|---|---|
| Founded | N/A | 2012 |
| Country | China | United States |
| Employees | N/A | N/A |
| Industry | Auto Parts:O.E.M. | Biotechnology: Pharmaceutical Preparations |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 134.9M | 140.4M |
| IPO Year | 2025 | 2020 |
| Metric | CAAS | CNTB |
|---|---|---|
| Price | $5.40 | $1.84 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 3 |
| Target Price | N/A | ★ $8.67 |
| AVG Volume (30 Days) | 47.9K | ★ 719.9K |
| Earning Date | 04-22-2026 | 08-13-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | N/A | ★ $64,000.00 |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | $3.97 | ★ N/A |
| Revenue Growth | ★ N/A | N/A |
| 52 Week Low | $4.00 | $1.23 |
| 52 Week High | $5.58 | $3.82 |
| Indicator | CAAS | CNTB |
|---|---|---|
| Relative Strength Index (RSI) | 63.29 | 45.59 |
| Support Level | $4.28 | $2.08 |
| Resistance Level | N/A | $2.74 |
| Average True Range (ATR) | 0.28 | 0.24 |
| MACD | 0.06 | -0.00 |
| Stochastic Oscillator | 79.19 | 3.11 |
China Automotive Systems Inc is a holding company. The firm, through its subsidiary, is a supplier of power steering systems and components to China's automotive industry. Its product offering encompasses a full range of auto parts incorporated into steering systems for both passenger automobiles and commercial vehicles. The company offers four separate series of power steering models, including rack and pinion power steering, integral power steering, electronic power steering, steering columns, steering oil pumps, and steering hoses. Geographically, it derives a majority of its revenue from China.
Connect Biopharma Holdings Ltd is a clinical-stage biopharmaceutical company dedicated to transforming care for asthma and chronic obstructive pulmonary disease (COPD). The company is advancing rademikibart, a next-generation antibody designed to target interleukin-4-receptor alpha. It is currently conducting clinical studies of rademikibart for the treatment of acute exacerbations of asthma and COPD. The company operates in one operating segment: treatment of respiratory diseases.